MOULDER LEON O JR 4
4 · Zenas BioPharma, Inc. · Filed Mar 31, 2026
Research Summary
AI-generated summary of this filing
Zenas BioPharma (ZBIO) CEO Leon Moulder Buys 54,000 Shares
What Happened
Leon O. Moulder Jr., CEO and Chairman of Zenas BioPharma (ZBIO), made two open‑market purchases (code P) totaling 54,000 shares. On 2026‑03‑30 he acquired 20,000 shares at a weighted average price of $18.23 (≈ $364,600). On 2026‑03‑31 he acquired 34,000 shares at a weighted average price of $19.31 (≈ $656,540). Total consideration for both purchases was about $1,021,140. These are outright purchases (a buy), which investors often view as a more directly informative signal than routine sales.
Key Details
- Transaction dates: 2026‑03‑30 (20,000 shares @ $18.23 weighted avg) and 2026‑03‑31 (34,000 shares @ $19.31 weighted avg).
- Reported totals: $364,600 (Mar 30) + $656,540 (Mar 31) = ~$1,021,140.
- Filing date: Form 4 filed 2026‑03‑31 (appears timely under Form 4 reporting rules).
- Shares owned after transaction: not specified in the information provided in this summary / not disclosed in the excerpt.
- Footnotes of note:
- F1/F3: Reported prices are weighted averages; purchases occurred in multiple trades within the stated price ranges (Mar 30 range $18.195–$18.25; Mar 31 range $18.84–$19.58). The reporting person can provide per‑trade breakdown on request.
- F2/F4: Some shares are held by Tellus BioVentures LLC and the Leon O. Moulder, Jr. Revocable Trust; Mr. Moulder is Managing Member/Trustee and may be deemed to have voting/dispositive power over those holdings but disclaims beneficial ownership except for his pecuniary interest.
Context
- These were open‑market purchases (not option exercises, gifts, or awards). Purchases by an executive can signal confidence, but filings don’t state motive.
- The holding entities (Tellus, the Trust) indicate some purchases may be held by entities associated with Mr. Moulder rather than directly in his name; that’s common but means ownership attribution has institutional/estate structure aspects.
Insider Transaction Report
Form 4
MOULDER LEON O JR
DirectorSee Remarks
Transactions
- Purchase
Common Stock
[F1][F2]2026-03-30$18.23/sh+20,000$364,600→ 1,692,039 total(indirect: See Footnote) - Purchase
Common Stock
[F3][F2]2026-03-31$19.31/sh+34,000$656,540→ 1,726,039 total(indirect: See Footnote)
Holdings
- 36,928(indirect: See Footnote)
Common Stock
[F4] - 423,155
Common Stock
Footnotes (4)
- [F1]The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $18.195 to $18.25, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F2]Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- [F3]The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $18.84 to $19.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F4]The reporting person is a Trustee of the Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008 (the "Trust") and may be deemed to have voting and dispositive power over the shares held by the Trust. The reporting person is the Issuer's chief executive officer and Chairman of its board of directors. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Signature
By: /s/ Chase Jayasekera, Attorney-in-Fact|2026-03-31